Snyder R, Bishop J, Brodie G, Burns W, Coates A, Levi J, Raghavan D, Schwarz M, Tattersall M, Thomson D
Cancer Treat Rep. 1987 Mar;71(3):273-6.
Epirubicin was studied in a phase I setting to find the maximum tolerated dose when given weekly for 3 of 4 weeks. Forty-one evaluable patients were treated in groups at doses increasing from 20 to 45 mg/m2. The highest dose level produced the maximum degree of myelosuppression (lowest neutrophil count, 1.9 X 10(9)/L; range, 0-3.7) recorded on Day 22. This was well-tolerated in this group of mainly pretreated patients. Nonhematologic side effects were minimal. This dose schedule allows a greater dose per unit time to be administered than other recommended schedules for epirubicin.
对表柔比星进行了I期研究，以确定在4周中的3周每周给药时的最大耐受剂量。41例可评估患者按剂量从20mg/m²递增至45mg/m²分组接受治疗。最高剂量水平导致在第22天记录到最大程度的骨髓抑制（最低中性粒细胞计数，1.9×10⁹/L；范围，0 - 3.7）。在这组主要为经预处理的患者中，该剂量耐受性良好。非血液学副作用极小。与其他推荐的表柔比星给药方案相比，该剂量方案允许每单位时间给予更大的剂量。
